Adherium Senior Management Update

Melbourne, Australia – 30 May 2022: Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions is pleased to announce the appointment of Tara Creaven-Capasso as its Vice President of Quality, Regulatory and Clinical Affairs.

In addition, Robert Spurr's interim CFO assignment has concluded and recruiting for the backfill of this Melbourne-based position is progressing.

Commenting on Mrs. Creaven-Capasso's appointment, Rick Legleiter, Adherium's Chief Executive Officer, said, "At this pivotal time in our growth strategy, we are extremely pleased to welcome Tara further strengthening our team. Her commercial pathway experience with the regulatory strategy and clinical trial management along with her excellent relationships and extensive background successfully negotiating with the FDA and other regulatory bodies will drive Adherium's market expansion forward."

As Adherium launches new products to grow its respiratory eHealth strategy, the strong regulatory, quality, and clinical capabilities the Company is consolidating and further developing, will increase market availability throughout the world, as well as create a competitive advantage in an increasingly regulated global environment. This new role is based in Adherium's corporate headquarters in Melbourne, Australia.

With over two decades of experience in the medical device, pharmaceutical, bioscience, and vaccine sectors, Mrs. Creaven-Capasso joins Adherium from COVID-19 Vaccine Corporation Ltd. (CVC), which she co-founded in 2020 and held quality and regulatory responsibilities of a COVID-19 vaccine. Prior to CVC, career highlights include co-founding an international consulting organisation, Caduceus Medical Development, with offices in the USA and New Zealand.

Before Caduceus Medical Development, Mrs. Creaven-Capasso based in the USA held positions of increasing responsibility based at several global organisations, including Xoma Inc., Elan Pharmaceuticals Inc., Arterial Vascular Engineering Inc., Medtronic Inc, ISTA Pharmaceuticals Inc., and Bluegrass Vascular Technologies Inc.

Mrs. Creaven-Capasso is an elected Fellow (holding the FRAPS and RAC designation) with the Regulatory Affairs Professionals Society (RAPS) and is a Registered Quality Assurance Professionals in Good Laboratory Practice (RQAP-GLP) with the Society of Quality Assurance (SQA).

Commenting on her appointment, Mrs. Creaven-Capasso said, "I have dedicated my career to bringing innovative technologies to market, for the purpose of improving patient's quality of life, while solving clinical problems. Development of robust regulatory strategies and quality management systems is essential when looking to commercialize and achieve market access of high quality, competitive, and compliant products. I am honoured to take on a broader role with the Adherium team to help deliver on its mission. I look forward to applying my expertise in guiding the Company as it continues to build on its commercial strategies."

About Adherium (ASX: ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management.

The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at www.adherium.com

This ASX announcement was approved and authorised for release by the Board of Adherium.

Enquiries: WE Communications
WE-AUAdherium@we-worldwide.com